Compare Smith & Nephew plc (SNN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs GeneDx Holdings Corp — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Smith & Nephew plc is far larger — about 7× GeneDx Holdings Corp's market cap, and Smith & Nephew plc pays a 2.57% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SNN | WGS | |
|---|---|---|
Market Cap | $12.64B | $1.80B |
Sector | Health | Technology |
52-Week High | $38.70 | $167.51 |
52-Week Low | $28.73 | $34.51 |
Enterprise Value | $15.41B | $1.80B |
Dividend Yield | 2.57% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
